Suppr超能文献

新辅助放化疗联合手术治疗食管癌患者术前病理肿瘤侵犯程度的外部验证。

External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.

机构信息

Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany.

Department of Surgery, Erasmus MC - University Medical Centre, Rotterdam, The Netherlands.

出版信息

Ann Surg Oncol. 2020 Apr;27(4):1250-1258. doi: 10.1245/s10434-019-08024-0. Epub 2019 Nov 5.

Abstract

BACKGROUND

This study was conducted to validate a pretreatment (i.e. prior to neoadjuvant chemoradiotherapy) pathological staging system in the resection specimen after neoadjuvant chemoradiotherapy for esophageal cancer. The study investigated the prognostic value of pretreatment pathological T and N categories (prepT and prepN categories) in both an independent and a combined patient cohort.

METHODS

Patients with esophageal cancer treated with neoadjuvant chemotherapy and esophagectomy between 2012 and 2015 were included. PrepT and prepN categories were estimated based on the extent of tumor regression and regressional changes of lymph nodes in the resection specimen. The difference in Akaike's information criterion (ΔAIC) was used to assess prognostic performance. PrepN and ypN categories were combined to determine the effect of nodal sterilization on prognosis. A multivariable Cox regression model was used to identify combined prepN and ypN categories as independent prognostic factors.

RESULTS

The prognostic strength of the prepT category was better than the cT and ypT categories (ΔAIC 7.7 vs. 3.0 and 2.9, respectively), and the prognostic strength of the prepN category was better than the cN category and similar to the ypN category (ΔAIC 29.2 vs. - 1.0 and 27.9, respectively). PrepN + patients who became ypN0 had significantly worse survival than prepN0 patients (2-year overall survival 69% vs. 86% in 137 patients; p = 0.044). Similar results were found in a combined cohort of 317 patients (2-year overall survival 62% vs. 85%; p = 0.002). Combined prepN/ypN stage was independently associated with overall survival.

CONCLUSIONS

These results independently confirm the prognostic value of prepTNM staging. PrepTNM staging is of additional prognostic value to cTNM and ypTNM. PrepN0/ypN0 patients have a better survival than prepN +/ypN0 patients.

摘要

背景

本研究旨在验证一种新辅助放化疗后食管癌切除术标本的预处理(即新辅助放化疗前)病理分期系统。该研究在独立和联合患者队列中调查了预处理病理 T 分期和 N 分期(prepT 和 prepN 分期)的预后价值。

方法

纳入 2012 年至 2015 年间接受新辅助化疗和食管切除术治疗的食管癌患者。基于切除标本中肿瘤消退程度和淋巴结消退变化,估计了 prepT 和 prepN 分期。Akaike 信息准则(AIC)差值用于评估预后性能。将 prepN 和 ypN 分期结合起来确定淋巴结绝育对预后的影响。采用多变量 Cox 回归模型确定联合 prepN 和 ypN 分期作为独立预后因素。

结果

与 cT 和 ypT 分期相比,prepT 分期的预后强度更好(AIC 差值分别为 7.7、3.0 和 2.9),与 cN 分期相比,prepN 分期的预后强度更好,与 ypN 分期相似(AIC 差值分别为 29.2、-1.0 和 27.9)。ypN0 的 prepN + 患者的总生存明显差于 prepN0 患者(137 例患者的 2 年总生存率为 69%比 86%,p=0.044)。在 317 例联合队列中也发现了类似的结果(2 年总生存率为 62%比 85%,p=0.002)。联合 prepN/ypN 分期与总生存独立相关。

结论

这些结果独立证实了 prepTNM 分期的预后价值。prepTNM 分期对 cTNM 和 ypTNM 具有额外的预后价值。prepN0/ypN0 患者的生存优于 prepN +/ypN0 患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0001/7060166/02b2063dc483/10434_2019_8024_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验